Secondary Hyperparathyroidism: A Hidden Danger in Chronic Kidney Disease

Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease
Sprague SM, Crawford PW, Melnick JZ, et al. Use of extended-release calcifediol to treat secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease. *Am J Nephrol*. 2016;44(4):316-325. doi:10.1159/000450766

Link: https://pubmed.ncbi.nlm.nih.gov/27676085/

Mechanisms of vascular calcification in kidney disease
Disthabanchong S, Srisuwarn P. Mechanisms of vascular calcification in kidney disease. *Adv Chronic Kidney Dis*. 2019;26(6):417-426. doi:10.1053/j.ackd.2019.08.014

Link: https://www.akdh.org/article/S1548-5595(19)30154-5/fulltext

High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial
Alvarez JA, Law J, Coakley KE, et al. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. *Am J Clin Nutr*. 2012;96(3):672-679. doi:10.3945/ajcn.112.040642

Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3417221/

Extended-release calcifediol in stage 3-4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D
Cozzolino M, Minghetti P, Navarra P. Extended-release calcifediol in stage 3-4 chronic kidney disease: a new therapy for the treatment of secondary hyperparathyroidism associated with hypovitaminosis D. *J Nephrol*. 2022;35(3):863-873. doi:10.1007/s40620-021-01152-5

Link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995284/

KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). *Kidney Int Suppl (2011)*. 2017;7(1):1-59. doi:10.1016/j.kisu.2017.04.001

Link: https://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Update.pdf

Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial

Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. *JAMA.* 2012;307(7):674-684. doi:10.1001/jama.2012.120

Link: https://jamanetwork.com/journals/jama/fullarticle/1104984

Effect of paricalcitol on left ventricular mass and function in CKD—the OPERA trial

Wang AYM, Fang F, Chan J, et al. Effect of paricalcitol on left ventricular mass and function in CKD—the OPERA trial. *J Am Soc Nephrol*. 2014;25(1):175-186. doi:10.1681/ASN.2013010103

Link:https://journals.lww.com/jasn/pages/articleviewer.aspx?year=2014&issue=01000&article=00021&type=Fulltext